Cargando…
Rewiring Lipid Metabolism by Targeting PCSK9 and HMGCR to Treat Liver Cancer
SIMPLE SUMMARY: We targeted abnormalities in lipid metabolism of liver cancer cells and showed that tumoral addiction to lipids can be potentially overridden by available drugs. Anti-PCSK9 alone or in combination with statin treatment can live up to this challenge and disrupt the process of oncogene...
Autores principales: | Alannan, Malak, Trézéguet, Véronique, Amoêdo, Nivea Dias, Rossignol, Rodrigue, Mahfouf, Walid, Rezvani, Hamid Reza, Dittrich-Domergue, Franziska, Moreau, Patrick, Lacomme, Sabrina, Gontier, Etienne, Grosset, Christophe F., Badran, Bassam, Fayyad-Kazan, Hussein, Merched, Aksam J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9817797/ https://www.ncbi.nlm.nih.gov/pubmed/36612001 http://dx.doi.org/10.3390/cancers15010003 |
Ejemplares similares
-
Targeting PCSK9 in Liver Cancer Cells Triggers Metabolic Exhaustion and Cell Death by Ferroptosis
por: Alannan, Malak, et al.
Publicado: (2022) -
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity
por: Alannan, Malak, et al.
Publicado: (2022) -
Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism
por: Trézéguet, Véronique, et al.
Publicado: (2021) -
Xeroderma Pigmentosum C (XPC) Mutations in Primary Fibroblasts Impair Base Excision Repair Pathway and Increase Oxidative DNA Damage
por: Fayyad, Nour, et al.
Publicado: (2020) -
Proteomic Study of Low-Birth-Weight Nephropathy in Rats
por: Imasawa, Toshiyuki, et al.
Publicado: (2021)